{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:39:13Z","timestamp":1774492753385,"version":"3.50.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1002\/jps.22030","type":"journal-article","created":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T19:33:11Z","timestamp":1259868791000},"page":"2544-2556","source":"Crossref","is-referenced-by-count":114,"title":["Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Furosemide"],"prefix":"10.1016","volume":"99","author":[{"given":"G.E","family":"Granero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.E.","family":"Junginger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.K.","family":"Midha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Stavchansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Barends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.22030_bb0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jps.20131","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on Biopharmaceutics Classification System (BCS). Literature data: Verapamil Hydrochloride, Propranolol Hydrochloride, and Atenolol","volume":"93","author":"Vogelpoel","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jps.20477","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (Paracetamol)","volume":"95","author":"Kalantzi","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0015","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/jps.21282","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Acetazolamide","volume":"97","author":"Granero","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0020","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1002\/jps.21392","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir","volume":"97","author":"Arnal","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0025","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/jps.20615","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline Hydrochloride","volume":"95","author":"Manzo","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0030","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/jps.20343","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chlor-oquine sulfate, and chloroquine hydrochloride","volume":"94","author":"Verbeeck","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0035","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jps.20614","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine","volume":"95","author":"Jantratid","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0040","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/jps.21525","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium","volume":"98","author":"Chuasuwan","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0045","series-title":"Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate","author":"Jantratid","year":"2009"},{"key":"10.1002\/jps.22030_bb0050","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/jps.21061","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride","volume":"97","author":"Becker","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0055","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/jps.20444","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen","volume":"94","author":"Potthast","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0060","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jps.20765","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid","volume":"96","author":"Becker","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0065","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1002\/jps.21276","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Metoclopramide hydrochloride","volume":"97","author":"Stosik","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jps.20768","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone","volume":"96","author":"Vogt","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0075","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jps.20817","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Prednisone","volume":"96","author":"Vogt","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0080","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/jps.21250","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide","volume":"97","author":"Becker","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0085","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/jps.21606","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Quinidine sulfate","volume":"98","author":"Grube","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0090","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/jps.20392","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride","volume":"94","author":"Kortejarvi","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0095","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/jps.21624","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: Rifampicine","volume":"98","author":"Becker","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0100","series-title":"Martindale: The complete drug reference","year":"2009"},{"key":"10.1002\/jps.22030_bb0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0378-5173(02)00586-0","article-title":"Physicochemical characterization of solid dispersion of furosemide with TPGS","volume":"251","author":"Shin","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.22030_bb0110","first-page":"304","article-title":"Some aspects of the photochemical degradation of frusemide","volume":"51","author":"Rowbotham","year":"1976","journal-title":"Pharm Acta Helv"},{"key":"10.1002\/jps.22030_bb0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2007.05.039","article-title":"Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes","volume":"345","author":"Devarakonda","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.22030_bb0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejpb.2005.12.006","article-title":"A new nanocarrier consisting of chitosan and hydroxypropyl- cyclodextrin","volume":"63","author":"Maestrelli","year":"2006","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.22030_bb0125","series-title":"Combined assessment of dissolution and epithelial permeability of solid oral dosage forms","author":"Motz","year":"2007"},{"key":"10.1002\/jps.22030_bb0130","series-title":"Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability","author":"WHO","year":"2006"},{"key":"10.1002\/jps.22030_bb0135","series-title":"Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System","author":"FDA","year":"2000"},{"key":"10.1002\/jps.22030_bb0140","series-title":"Note for guidance on the investigation of bioavailability and bioequivalence","author":"EMEA","year":"2001"},{"key":"10.1002\/jps.22030_bb0145","series-title":"Draft Guideline on the Investigation of Bioequivalence","author":"EMEA","year":"2008"},{"key":"10.1002\/jps.22030_bb0150","series-title":"USP;1; 32\u2014NF 27. The United States Pharmacopeia\u2014The National Formulary","author":"The United States Pharmacopeial Convention, Inc","year":"2009"},{"key":"10.1002\/jps.22030_bb0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0378-5173(90)90185-7","article-title":"Physicochemical characterization of furosemide modifications","volume":"60","author":"Matsuda","year":"1990","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.22030_bb0160","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1081\/DDC-100100271","article-title":"Structure-solubility relationship and thermal decomposition of furosemide","volume":"26","author":"Beyers","year":"2000","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1002\/jps.22030_bb0165","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jps.20302","article-title":"Trends in solubility of polymorphs","volume":"94","author":"Pudipeddi","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0170","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cplett.2006.08.080","article-title":"Molecular dynamics of solid furosemide (4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid) studied by NMR and DFT methods","volume":"430","author":"Latosinska","year":"2006","journal-title":"Chem Phy Lett"},{"key":"10.1002\/jps.22030_bb0175","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/ac9810563","article-title":"Hydrophobicity of ionizable compounds. A theoretical study and measurements of diuretic octanol-water partition coefficients by countercurrent chromatography","volume":"71","author":"Berthod","year":"1999","journal-title":"Anal Chem"},{"key":"10.1002\/jps.22030_bb0180","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.chroma.2003.10.097","article-title":"Micellar versus hydro-organic mobile phases for retention-hydrophobicity relationship studies with ionizable diuretics and an anionic surfactant","volume":"1030","author":"Ruiz-Angel","year":"2004","journal-title":"J Chromatogr A"},{"key":"10.1002\/jps.22030_bb0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.22030_bb0190","unstructured":"WHO. WHO model list of essential medicines. 16th list, March 2009. http:\/\/www.who.int\/selection_medicines\/committees\/expert\/17\/WEB_unedited_16th_LIST.pdf. (accessed May 8, 2009)."},{"key":"10.1002\/jps.22030_bb0195","unstructured":"ROTE LISTE\u00ae Arzneimittelverzeichnis f\u00fcr Deutschland. http:\/\/www.rote-liste.de. (accessed May 8, 2009)."},{"key":"10.1002\/jps.22030_bb0200","unstructured":"The Danish Medicines Agency. www.dkma.dk. (accessed May 8, 2009)."},{"key":"10.1002\/jps.22030_bb0205","unstructured":"National Agency for Medicines. http:\/\/www.nam.fi. (accessed May 15, 2009)."},{"key":"10.1002\/jps.22030_bb0210","unstructured":"VIDAL. Fiches medicaments. www.vidal.fr. (accessed May 15, 2009)."},{"key":"10.1002\/jps.22030_bb0215","unstructured":"College ter Beoordeling van Geneesmiddelen\u2014Medicines Evaluation Board. http:\/\/www.cbg-meb.nl. (accessed May 8, 2009)."},{"key":"10.1002\/jps.22030_bb0220","unstructured":"Norwegian Medicines Agency. www.legemiddelverket.no. (accessed May 15, 2009)."},{"key":"10.1002\/jps.22030_bb0225","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. www.agemed.es.. (accessed May 15, 2009)."},{"key":"10.1002\/jps.22030_bb0230","unstructured":"Lakemedelsverketwww.lakemedelsverket.se.. (accessed May 15, 2009)."},{"key":"10.1002\/jps.22030_bb0235","unstructured":"Datapharm Communications Ltd.www.medicines.org.uk.(accessed May 15, 2009)."},{"key":"10.1002\/jps.22030_bb0240","unstructured":"DailyMed. http:\/\/www.dailymed.\u00f1lm.\u00f1ih.gov. (accessed May 15, 2009)."},{"key":"10.1002\/jps.22030_bb0245","first-page":"381","article-title":"Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (Part I)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.22030_bb0250","first-page":"460","article-title":"Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (Part II)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.22030_bb0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00630286","article-title":"Pharmacokinetics of furosemide in man after intravenous and oral administration: Application of moment analysis","volume":"26","author":"Hammarlund","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.22030_bb0260","first-page":"178","article-title":"Pharmacokinetics of orally administered furosemide","volume":"15","author":"Kelly","year":"1973","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.22030_bb0265","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF00556898","article-title":"Implications of i\u00f1trai\u00f1dividual variability in bioavailability studies of furosemide","volume":"27","author":"Grah\u00f1t\u00ed\u00f1","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.22030_bb0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0378-5173(79)90095-4","article-title":"Gastrointestinal sites of furosemide absorption in rats","volume":"4","author":"Chungi","year":"1979","journal-title":"I\u00f1t J Pharm"},{"key":"10.1002\/jps.22030_bb0275","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0928-0987(01)00134-8","article-title":"Evaluation of the i\u00f1telisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon","volume":"13","author":"Clear","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0280","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/bod.2510090209","article-title":"Comparative bioavailability of furosemide from solution and 40mg tablets with different dissolution characteristics following oral administration in normal men","volume":"9","author":"Waller","year":"1988","journal-title":"Biopharm Drug Dis"},{"key":"10.1002\/jps.22030_bb0285","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1023\/A:1016427321532","article-title":"Influence of tablet dissolution of furosemide bioavailability: A bioequivalence study","volume":"4","author":"McNamara","year":"1987","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22030_bb0290","first-page":"178","article-title":"Pharmacokinetics of orally administered furosemide","volume":"15","author":"Kelly","year":"1973","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.22030_bb0295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-197904040-00002","article-title":"Clinical pharmacokinetics of frusemide","volume":"4","author":"Cutler","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.22030_bb0300","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/BF00615967","article-title":"Reduced bioavailability and effect of furosemide given with foof","volume":"29","author":"Beermann","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.22030_bb0305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/bdd.2510060202","article-title":"Pharmacokinetics of furosemide after three different single oral doses","volume":"6","author":"Waller","year":"1985","journal-title":"Biopharm Drug Dispos"},{"key":"10.1002\/jps.22030_bb0310","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0090-9556(25)00282-X","article-title":"Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay","volume":"8","author":"Smith","year":"1980","journal-title":"Drug Metab Dis"},{"key":"10.1002\/jps.22030_bb0315","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/jps.2600711006","article-title":"Disposition and absolute bioavailability of furosemide in healthy males","volume":"71","author":"Waller","year":"1982","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0320","first-page":"S-396","article-title":"Human effective permeability data for furosemide, hydrochlothiazide, ketoprofen and naproxen to be used in the proposed biopharmaceutical classification for IR products","volume":"12","author":"Lennernas","year":"1995","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22030_bb0325","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0928-0987(00)00076-2","article-title":"Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells","volume":"10","author":"Yamashita","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0330","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejps.2005.11.005","article-title":"Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration on the method suitability","volume":"27","author":"Corti","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0335","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jpba.2005.12.020","article-title":"Prediction of the permeability of drugs through study on quantitative structure-permeability relationship","volume":"41","author":"Jung","year":"2006","journal-title":"J Pharm Biom Anal"},{"key":"10.1002\/jps.22030_bb0340","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/A:1018868123367","article-title":"Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat Jejunum","volume":"16","author":"Flanagan","year":"1999","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22030_bb0345","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1023\/A:1012111008617","article-title":"Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in Caco-2 cell culture model","volume":"14","author":"Pade","year":"1997","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22030_bb0350","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/jps.1127","article-title":"Effect of common excipients on Caco-2 transport of low-permeability drugs","volume":"90","author":"Rege","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0355","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/(SICI)1520-6017(200001)89:1<63::AID-JPS7>3.0.CO;2-6","article-title":"Caco-2 versus Caco-2\/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside directed carrier-mediated transport","volume":"89","author":"Hilgendorf","year":"2000","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0360","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1021\/jm9810102","article-title":"Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters A multivariate data analysis approach","volume":"41","author":"Winiwarter","year":"1998","journal-title":"J Med Chem"},{"key":"10.1002\/jps.22030_bb0365","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2005.11.005","article-title":"Influence of vitamin ETPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers","volume":"111","author":"Collnot","year":"2006","journal-title":"J Control Release"},{"key":"10.1002\/jps.22030_bb0370","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2125.1978.tb00880.x","article-title":"Bioavailability of two furosemide preparations","volume":"6","author":"Beermann","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jps.22030_bb0375","first-page":"403","article-title":"Bioavailability of furosemide","volume":"91","author":"Eggers","year":"1980","journal-title":"N Z Med J"},{"key":"10.1002\/jps.22030_bb0380","first-page":"476","article-title":"Bioequivalence studies with furosemide","volume":"92","author":"Habermann","year":"1980","journal-title":"N Z Med J"},{"key":"10.1002\/jps.22030_bb0385","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/jps.2600730404","article-title":"Comparative bioavailability of two furosemide formulations in humans","volume":"73","author":"Martin","year":"1984","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.22030_bb0390","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/bdd.2510070203","article-title":"Bioavailability of seven furosemide tablets in man","volume":"7","author":"Straughn","year":"1986","journal-title":"Biopharm Drug Dis"},{"key":"10.1002\/jps.22030_bb0395","first-page":"191","article-title":"Bioavailability and pharmacokinetics of furosemide marketed in Thailand","volume":"73","author":"Kaojarern","year":"1990","journal-title":"J Med Assoc Thai"},{"key":"10.1002\/jps.22030_bb0400","first-page":"18","article-title":"A bioequivalence study of two products of furosemide tablets","volume":"30","author":"Awad","year":"1992","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1002\/jps.22030_bb0405","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/bdd.361","article-title":"Bioequivalence evaluation of two brands of furosemide 40mg tablets (Salurin and Lasix) in healthy human volunteers","volume":"24","author":"Nakib","year":"2003","journal-title":"Biopharm Drug Dis"},{"key":"10.1002\/jps.22030_bb0410","first-page":"321","article-title":"In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations","volume":"53","author":"Cuadrado","year":"2003","journal-title":"Arzneimittelforschung Drug Res"},{"key":"10.1002\/jps.22030_bb0415","unstructured":"Yu LX. 2004. BioINequivalence: Concept and Definition. ACPS Meeting, October 19-20. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/slides\/2004-4078 S2_07_YU.ppt. (accessed October 25, 2009)."},{"key":"10.1002\/jps.22030_bb0420","first-page":"83","article-title":"Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters","volume":"16","author":"Wolf-Coporda","year":"1996","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1002\/jps.22030_bb0425","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3109\/03639047809081826","article-title":"The effect of four tablet binders on the bioavailability of frusemide from 40MG tablets","volume":"4","author":"Rubinstein","year":"1978","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1002\/jps.22030_bb0430","first-page":"693","article-title":"The pharmaceutical and biological availability of commercial preparations of furosemide","volume":"32","author":"St\u00fcber","year":"1982","journal-title":"Arzneimittelforschung Drug Res"},{"key":"10.1002\/jps.22030_bb0435","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0378-5173(82)90180-6","article-title":"Dissolution medium\u2014A critical parameter to identify bioavailability problems of furosemide tablets","volume":"11","author":"Prasad","year":"1982","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.22030_bb0440","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.2042-7158.1984.tb04446.x","article-title":"An in vivo-in vitro correlation for the bioavailability of frusemide tablets","volume":"36","author":"Kingsford","year":"1984","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.22030_bb0445","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3109\/03639049809089943","article-title":"Assessment of pharmaceutical quality of furosemide tablets from multinational markets","volume":"24","author":"Qureshi","year":"1998","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1002\/jps.22030_bb0450","series-title":"Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms","author":"WHO","year":"2006"},{"key":"10.1002\/jps.22030_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01059086","article-title":"Furosemide pharmacokinetics and pharmacodynamics in health and disease\u2014 An update","volume":"17","author":"Hammarlund-Idemaes","year":"1989","journal-title":"J Biopharmacokinet Biopharm"},{"key":"10.1002\/jps.22030_bb0460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"46","author":"Artursson","year":"2001","journal-title":"Adv Drug Del Rev"},{"key":"10.1002\/jps.22030_bb0465","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1023\/B:PHAM.0000008037.57884.11","article-title":"Quantitative biopharmaceutics classification system: The central role of dose\/ solubility ratio","volume":"20","author":"Rinaki","year":"2003","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22030_bb0470","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1023\/A:1011919003030","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line","volume":"15","author":"Gres","year":"1998","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22030_bb0475","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur J Pham Biopharm"},{"key":"10.1002\/jps.22030_bb0480","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: Transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22030_bb0485","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1002\/jps.22030_bb0490","unstructured":"FDA. Code of Federal Regulations. Title 21, Part 320: Bioavailability and Bioequivalence requirements. Section 320.33. 2003. http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=320.33. (accessed May 18, 2009)."},{"key":"10.1002\/jps.22030_bb0495","unstructured":"PAHO. Science based criteria for bioequivalence in vivo and in vitro, biowaivers, and strategic framework for implementation. http:\/\/www.paho.org\/english\/ad\/ths\/ev\/be-doct-draft-eng.pdf. (accessed May 18, 2009)"},{"key":"10.1002\/jps.22030_bb0500","series-title":"Guidance for Industry. Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. (SUPAC-IR)","author":"FDA","year":"2005"},{"key":"10.1002\/jps.22030_bb0505","series-title":"Guideline on Dossier requirements for Type IA and Type IB","author":"European Commission","year":"2006"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915326034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915326034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T16:24:56Z","timestamp":1739463896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915326034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0022354915326034"],"URL":"https:\/\/doi.org\/10.1002\/jps.22030","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}